What's Happening?
Agenus Inc. has announced the publication of positive results from the investigator-sponsored, multicenter Phase 2 UNICORN trial in Nature Medicine. The trial evaluated botensilimab (BOT), Agenus’ anti-CTLA-4 antibody, alone or in combination with balstilimab
(BAL), Agenus’ anti-PD-1 antibody, in patients with resectable, locally advanced colon cancer. The study enrolled 56 patients across four non-randomized cohorts, assessing BOT alone or BOT+BAL in mismatch repair proficient/microsatellite stable (pMMR/MSS) and mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) colon cancer. Key findings include a 36% major pathologic response rate and 29% pathologic complete response rate in pMMR/MSS colon cancer patients treated with BOT+BAL, with an overall 71% pathologic response rate. In dMMR/MSI-H disease, all 14 patients (100%) in the BOT+BAL cohort achieved a major pathologic response, with 93% achieving a pathologic complete response. The responses were durable, with no cancer recurrence observed in BOT+BAL treated patients at a median follow-up of 19.2 months in pMMR/MSS disease and 16.7 months in dMMR/MSI-H disease. All 56 patients underwent surgical resection, and Grade 3 or 4 immune-related adverse events occurred in only 2% of patients.
Why It's Important?
These trial results are significant because pMMR/MSS colon cancer, which accounts for approximately 85% of early-stage colorectal cancers, has historically shown limited benefit from conventional immunotherapy. The observed deep pathologic responses and 100% 12-month event-free survival in both BOT+BAL combination cohorts suggest a potential paradigm shift in treating this patient population. For historical context, first-generation CTLA-4/PD-1 combination immunotherapy has shown an MPR rate of approximately 20%, and neoadjuvant chemotherapy an 8% MPR rate in pMMR colon cancer. The ability of BOT+BAL to induce such responses earlier in the disease course, before surgery, could lead to improved patient outcomes by potentially eliminating residual disease and preventing recurrence. The consistency of these findings with the previously published NEST study further strengthens the clinical evidence for BOT+BAL, providing a strong foundation for Agenus' planned Phase 3 ROBBIN trial. This could offer a new, more effective treatment option for a large segment of colon cancer patients who currently have limited immunotherapy options.
What's Next?
Agenus is advancing its planned global randomized Phase 3 ROBBIN trial, which will evaluate neoadjuvant BOT+BAL followed by standard of care versus standard of care alone in previously untreated patients with high-risk Stage II or Stage III MSS/pMMR colon cancer. Event-free survival will be the primary endpoint for this trial. The successful completion and positive outcomes of the ROBBIN trial could pave the way for regulatory submissions and potential market approval of BOT+BAL as a neoadjuvant treatment for MSS colon cancer. Further research will likely focus on long-term follow-up data from the UNICORN trial to confirm the durability of responses and overall survival benefits. Additionally, continued translational research, including analysis of circulating tumor DNA (ctDNA) clearance and immune environment remodeling, will provide deeper insights into the mechanisms of action and help identify patient populations most likely to benefit from this therapy. The medical community will be closely watching the progress of the ROBBIN trial, as its success could fundamentally alter the treatment landscape for early-stage colon cancer.
Beyond the Headlines
The UNICORN trial's findings extend beyond immediate clinical efficacy, offering deeper insights into the biological mechanisms of immunotherapy in previously resistant tumors. The observed alignment between deep pathologic responses, clearance of circulating tumor DNA (ctDNA), and changes within the tumor immune environment provides a comprehensive understanding of treatment activity. This suggests that BOT's Fc-enhanced design effectively remodels the tumor microenvironment, reducing immunosuppressive regulatory T-cells and increasing immune-cell infiltration. This mechanistic understanding is crucial for developing more targeted and effective immunotherapies in the future. The success in MSS colon cancer, historically considered immunologically 'cold,' challenges long-held assumptions about tumor responsiveness to immunotherapy and opens new avenues for research into other 'cold' tumors. Ethically, the potential for a curative-intent treatment in early-stage disease could significantly improve quality of life and reduce the burden of advanced cancer, shifting the focus towards earlier intervention and prevention of recurrence. This development could also influence public policy regarding cancer screening and early treatment strategies, potentially leading to better patient access to innovative therapies.
